Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Operating Margin (2021 - 2025)

Historic Operating Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 13.28%.

  • Kiniksa Pharmaceuticals International's Operating Margin rose 218900.0% to 13.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.38%, marking a year-over-year increase of 132100.0%. This contributed to the annual value of 10.78% for FY2024, which is 14500.0% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Operating Margin stood at 13.28% for Q3 2025, which was up 218900.0% from 12.86% recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Operating Margin peaked at 46.82% during Q3 2022, and registered a low of 526.41% during Q2 2021.
  • Moreover, its 5-year median value for Operating Margin was 12.18% (2024), whereas its average is 62.63%.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Operating Margin skyrocketed by 4546100bps in 2022, and later tumbled by -631200bps in 2023.
  • Kiniksa Pharmaceuticals International's Operating Margin (Quarter) stood at 192.75% in 2021, then soared by 98bps to 4.08% in 2022, then skyrocketed by 102bps to 0.1% in 2023, then crashed by -16315bps to 15.75% in 2024, then soared by 184bps to 13.28% in 2025.
  • Its Operating Margin was 13.28% in Q3 2025, compared to 12.86% in Q2 2025 and 9.63% in Q1 2025.